GlassScriptPhysician profile
Ryan Andrew Armour
NPI 1003080557
$4,041.14
in general payments reported to CMS, 2019-2025
39 companies · $97.93 in 2025
The $97.93 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20.70 · 2021: $22.35 · 2022: $594 · 2023: $2,750 · 2024: $557 · 2025: $97.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,368 · Education: $35.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,368.49 |
| Education | $35.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $491.24 | 2022-2024 | Ubrelvy, Qulipta, Vraylar |
| Argenx US, INC. | $285.85 | 2023-2024 | Vyvgart, Vyvgart Hytrulo |
| Sk Life Science, INC. | $247.77 | 2022-2023 | |
| Teva Pharmaceuticals USA, INC. | $228.16 | 2023-2024 | Austedo Xr, Ajovy, Austedo |
| Ge Healthcare | $213.13 | 2022-2025 | |
| Lilly USA, LLC | $212.70 | 2022-2023 | Mounjaro |
| Neurocrine Biosciences, INC. | $209.84 | 2022-2023 | Ingrezza, Ongentys |
| Genentech USA, INC. | $200.70 | 2022-2023 | Ocrevus, Enspryng |
| Celgene Corporation | $178.14 | 2023 | Zeposia |
| Amgen INC. | $136.17 | 2022-2023 | Enbrel, Otezla, Tavneos |
| Amylyx Pharmaceuticals, INC. | $131.68 | 2023 | Relyvrio |
| Abbott Laboratories | $115.90 | 2022-2023 | Proclaim, Infinity |
| Janssen Biotech, INC. | $109.83 | 2023 | Tremfya, Simponi Aria |
| Boston Scientific Corporation | $105.20 | 2023 | Lux-Dx Insertable Cardiac Monitor |
| Medtronic, INC. | $104.00 | 2024 | Linq II |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $96.06 | 2022-2023 | Tysabri, Vumerity |
| Acadia Pharmaceuticals INC | $92.87 | 2022-2023 | Nuplazid |
| Bayer Healthcare Pharmaceuticals INC. | $87.39 | 2023 | |
| Pfizer INC. | $85.48 | 2023-2024 | |
| Axsome Therapeutics, INC. | $76.74 | 2025 | Symbravo |
| Alexion Pharmaceuticals, INC. | $70.03 | 2023 | Ultomiris |
| Aurinia Pharma U.S., INC. | $56.30 | 2023 | Lupkynis |
| Impel Pharmaceuticals INC. | $54.62 | 2022-2023 | Trudhesa |
| Ucb, INC. | $50.40 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $43.86 | 2022 | |
| Ani Pharmaceuticals, INC. | $41.18 | 2023 | Purified Cortrophin Gel |
| Novartis Pharmaceuticals Corporation | $34.41 | 2022-2023 | |
| Grt US Holding, INC. | $34.02 | 2022 | |
| Mdd US Operations, LLC | $31.58 | 2022-2023 | Gocovri |
| Halozyme INC | $29.56 | 2023 | |
| Insightec,INC | $28.00 | 2024 | Exablate |
| Radius Health, INC. | $23.18 | 2023 | Tymlos |
| Optinose US, INC. | $22.40 | 2023 | |
| Allergan, INC. | $22.35 | 2021 | |
| Livanova USA, INC. | $20.70 | 2019 | |
| Itamar Medical INC | $19.40 | 2023 | Watchpatone |
| Takeda Pharmaceuticals U.S.A., INC. | $18.00 | 2023 | |
| Sumitomo Pharma America, INC. | $16.49 | 2023 | Aptiom |
| Tandem Diabetes Care, INC. | $15.81 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Armour listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.